Lucentis (ranibizumab) / Roche, Novartis 
Welcome,         Profile    Billing    Logout  
 172 Diseases   135 Trials   135 Trials   7089 News 


«12...2324252627282930313233...7475»
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Preclinical, Journal:  Therapeutic Efficacy of a Novel Acetylated Tetrapeptide in Animal Models of Age-Related Macular Degeneration. (Pubmed Central) -  May 26, 2021   
    The preventive and therapeutic in vivo efficacy of Ac-RLYE via following intravitreal administration was determined to be either similar or superior to that of ranibizumab and aflibercept...Our results suggested that Ac-RLYE has a great potential for an alternative therapeutics for neovascular (wet) AMD. Since the amino acids in human VEGFR-2 targeted by Ac-RLYE are conserved among the animals employed in this study, the therapeutic efficacies of Ac-RLYE evaluated in those animals are predicted to be observed in human patients suffering from retinal degenerative diseases.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Clinical, Journal, HEOR:  Cost-effectiveness analysis of ranibizumab for retinal vein occlusion patients in China from the societal perspective. (Pubmed Central) -  May 25, 2021   
    Since the amino acids in human VEGFR-2 targeted by Ac-RLYE are conserved among the animals employed in this study, the therapeutic efficacies of Ac-RLYE evaluated in those animals are predicted to be observed in human patients suffering from retinal degenerative diseases. The current Markov model demonstrated that ranibizumab may be cost-effective compared with laser photocoagulation to treat BRVO and cost-effective compared to observation-only care to treat CRVO in China from the societal perspective.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
    Journal, Adverse events:  Drug-related adverse effects of antivascular endothelial growth factor agents. (Pubmed Central) -  May 22, 2021   
    The current Markov model demonstrated that ranibizumab may be cost-effective compared with laser photocoagulation to treat BRVO and cost-effective compared to observation-only care to treat CRVO in China from the societal perspective. Newer anti-VEGF agents pose a significant risk of adverse events not seen with routine anti-VEGF agents.
  • ||||||||||  Avastin (bevacizumab) / Roche, Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
    Journal:  One-Year Outcome of Aflibercept Intravitreal Injection in Vitrectomized Eyes with Diabetic Macular Edema. (Pubmed Central) -  May 20, 2021   
    P=N/A
    Thirty eyes were non-naïve and received previously thermal laser (44.3%), intravitreal injection of triamcinolone (26.7%), of ranibizumab (70%), of dexamethasone implant (36.7%), or bevacizumab (6.7%)...These results suggest that IAI may be beneficial in vitrectomized eyes with refractory DME which require frequent injections to obtain visual and anatomical improvement. http://www.clinicaltrials.gov, registration Number NCT02874859.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Clinical, Journal:  Efficacy of intravitreal Lucentis injection on major and macular branch retinal vein occlusion. (Pubmed Central) -  May 15, 2021   
    We should be aware of minimal inflammation after repeated intravitreal injections in order to establish the adequate treatment. To sum up, intravitreal injection of Lucentis was effective for both major and macular BRVO, and the efficacy in macular subtype group was better than that in major subtype group with the more obviously improvement and the less number of injections.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
    Clinical, Journal:  Cost-consequence analysis of extended loading dose of anti-VEGF treatment in diabetic macular edema patients. (Pubmed Central) -  May 15, 2021   
    To extend the anti-VEGF loading dose from 3 to 6 injections necessitates investing €5882.77 (8 injections), €10,091.03 (14 injections) and €10,198.59 (30 injections) per additional responder patient (3-month nonresponders and 6-month responders) to aflibercept, ranibizumab and bevacizumab, respectively. For the total of patients treated, on average €7927.02 (14 injections) per additional responder patient would be needed.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Enrollment change, Trial completion date, Trial termination:  Continuing Assessment of Patients Treated With ranibizUmab for REtinal Vein Occlusion (CAPTURE) (clinicaltrials.gov) -  May 14, 2021   
    P=N/A,  N=47, Terminated, 
    N=115 --> 47 | Trial completion date: Dec 2021 --> Mar 2021 | Active, not recruiting --> Terminated; The study was terminated as patients could not be followed-up during the COVID pandemic. Since this was a non-intervention study, as per Johns Hopkins University policy, we had to hold off the patient visits during the pandemic.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    [VIRTUAL] The Impact of the COVID-19 Pandemic on Aflibercept and Ranibizumab Anti-VEGF Injections () -  May 13, 2021 - Abstract #ARVO2021ARVO_3216;    
    Despite stay-at-home orders, there was no significant decrease in the overall number of aflibercept or ranibizumab injections during the COVID pandemic compared to the prior year. Although further information is needed to determine if these injections represent both new and return patients, these data suggest that in this specific population, patients still returned to their retina specialist for care despite the ongoing pandemic.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
    [VIRTUAL] Repeat Ranibizumab Injections in Retinopathy of Prematurity () -  May 13, 2021 - Abstract #ARVO2021ARVO_2945;    
    A second IVI was performed to allow further peripheral vascularization of the retina, with the added benefit of avoiding general anesthesia in critically ill infants until they are older. IVR was chosen because it has a shorter systemic half-life compared to bevacizumab, theoretically causing less side effects.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    [VIRTUAL] Incidence, severity and identification of risk factors of retinopathy of prematurity in our setting. () -  May 13, 2021 - Abstract #ARVO2021ARVO_2933;    
    Use of O2 and respiratory distress have been associated RF, however only sepsis and transfusions showed significant differences in our research. According with the expectation of growth in the incidence of this pathology due mainly to the advancement of life support maneuvers employed in modern pediatrics, we must continue to apply these screening criteria in our center, because it has allowed the early detection of all cases of severe ROP in our center.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    [VIRTUAL] DARC as a biomarker of endothelial cell stress in retinal angiogenesis () -  May 13, 2021 - Abstract #ARVO2021ARVO_2482;    
    This is the first time in vivo that DARC has been shown to identify phosphatidylserine in angiogenic processes, and illustrates its use as a biomarker for anti-angiogenic treatments. DARC can be therefore used in vivo to identify the earliest stages of leakage and angiogenesis in choroidal neovascularisation, diabetic eye disease and potentially any retinal disease in which pathological angiogenesis occurs.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    [VIRTUAL] AAO IRIS Registry data replicates VIEW 1 and VIEW 2 clinical trial outcome data () -  May 13, 2021 - Abstract #ARVO2021ARVO_2461;    
    The proportion of eyes losing <15 across the VIEW 1 and VIEW 2 studies was similar to our registry cohort, indicating proof-of-concept, although the mean gains in letters varied across the studies. Benchmarking real-world endpoints versus randomized controlled trials could be a valuable tool in validating the predictive ability of these endpoints as a measure of effectiveness.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    [VIRTUAL] In vitro characterization of ranibizumab release from the Port Delivery System () -  May 13, 2021 - Abstract #ARVO2021ARVO_2417;    
    P2
    Ranibizumab release from the PDS implant was demonstrated to be highly predictable and tunable based on a simple diffusion model. These findings support the median time to first refill of 15.8 months in Ladder PDS 100 mg/mL patients.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    [VIRTUAL] Identification of choroidal neovascularization activity using deep learning () -  May 13, 2021 - Abstract #ARVO2021ARVO_2166;    
    P3
    Our study demonstrated that a prototype DL model can accurately detect CNV disease activity based on changes in the retinal anatomy on OCT. While this algorithm needs to be validated on other datasets, it could potentially be applied for remote and automated monitoring of nAMD.